...
首页> 外文期刊>IJC Heart & Vasculature >A systematic review of biomarkers in Takotsubo syndrome: A focus on better understanding the pathophysiology
【24h】

A systematic review of biomarkers in Takotsubo syndrome: A focus on better understanding the pathophysiology

机译:Takotsubo综合征的生物标志物系统审查:重点是更好地理解病理生理学

获取原文
           

摘要

BackgroundThe diagnosis of Takotsubo syndrome is made based on clinical presentation, ECG, biomarker, imaging and coronary angiography. There is a lack of diagnostic biomarkers that can discriminate patients with Takotsubo syndrome from those with acute myocardial infarction (AMI) and provide clinical monitoring and prognostic information in the long-term.MethodsA literature search of published Takotsubo syndrome biomarkers from PubMed was performed. All studies that included numerical biomarker data on Takotsubo syndrome was included. Exclusion criteria was any study without an AMI cohort for comparison in the acute phase biomarkers or due to the absence of numerical values. The results were tabulated in table form with results expressed as either mean?±?SD or median (interquartile range).ResultsThe literature search produced 14 relevant studies that met search criteria.The results showed; high sensitivity Troponin I (3.21?±?4.4 vs 34.4?±?37?ng/ml), BNP [972 (578.5–1671.0) pg/L vs 358 (50.5–688.0) pg/L in NSTEMI and vs 381 (106.0–934.0) pg/L in STEMI] and BNP/Troponin I ratio [642 (331.8–1226.5) vs 184.5 (50.5–372.3) pg/ug in NSTEMI and 7.5 (2.0–29.6) pg/ug in STEMI] patients.DiscussionThis study is limited by many studies being retrospective cohort studies. This data shows that acutely troponin is raised in Takotsubo syndrome but not enough to be discriminating from AMI. BNP level is significantly raised in Takotsubo syndrome compared to AMI.ConclusionCurrent specificity of acute and chronic biomarkers for Takotsubo syndrome is lacking and further work is needed to address the gap in knowledge.
机译:背景技术基于临床介绍,心电图,生物标志物,成像和冠状动脉血管造影,制造了Takotsubo综合征的诊断。缺乏诊断生物标志物,可以将患有急性心肌梗死(AMI)的患者区分患者,并在长期内提供临床监测和预后信息。关于发表的高级综合征生物标志物的临床监测和预后信息。包括包含关于高岭土综合征的数值生物标志物数据的所有研究。排除标准是没有AMI队列的任何研究,用于在急性期生物标志物中或由于没有数值而进行比较。结果用表格表格列出,结果表达为平均值α±sd或中位数(四分位数范围)。方法研究了14项相关的研究,符合搜索标准。结果表明;高敏感性肌钙蛋白I(3.21?±4.4 vs 34.4?±37?Ng / ml),BNP [972(578.5-1671.0)PG / L与358(50.5-688.0)PG / L在NSTEMI和VS 381中(106.0 -934.0)pg / l在Stemi]和BNP /肌钙蛋白I的比例[642(331.8-1226.5)Vs 184.5(50.5-372.3)pg / ug在nstemi和7.5(2.0-29.6)pg / ug中的pg / ug。患者。iscussionthis研究受到许多研究的限制是回顾性队列研究。该数据显示,急性肌钙蛋白在Takotubo综合征中提出,但不足以歧视AMI。与AMI相比,BNP水平显着升高。与AMI相比,Takotsubo综合征有显着升高。急性和慢性生物标志物的特异性缺乏,需要进一步的工作来解决知识的差距。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号